enfortumab-话题@MedSci - 梅斯（MedSci）

#enfortumab#

8篇内容 | 670人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1785328, encodeId=24cc1e8532830, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, objectType=article, longId=724545, objectId=4673e2454541, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4673e2454541, replyNumber=0, likeNumber=102, createdTime=2022-07-01, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4673e2454541, moduleTitle=Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4673e2454541)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785323, encodeId=01d51e853237d, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, objectType=article, longId=207094, objectId=a84a20e094e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a84a20e094e5, replyNumber=0, likeNumber=97, createdTime=2021-06-18, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a84a20e094e5, moduleTitle=NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a84a20e094e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785327, encodeId=5a471e853273c, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, objectType=article, longId=211335, objectId=282e211335e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=282e211335e4, replyNumber=0, likeNumber=83, createdTime=2021-07-09, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=282e211335e4, moduleTitle=Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=282e211335e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785324, encodeId=06071e85324d0, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, objectType=article, longId=207205, objectId=96bf20e20583, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=96bf20e20583, replyNumber=0, likeNumber=66, createdTime=2021-10-14, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=96bf20e20583, moduleTitle=ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=96bf20e20583)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785325, encodeId=b2801e853257e, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, objectType=article, longId=209073, objectId=c97e2090e362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c97e2090e362, replyNumber=0, likeNumber=75, createdTime=2021-12-23, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c97e2090e362, moduleTitle=EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c97e2090e362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785326, encodeId=db771e85326a8, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）, objectType=article, longId=209110, objectId=46be20911056, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=46be20911056, replyNumber=0, likeNumber=76, createdTime=2021-09-30, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=46be20911056, moduleTitle=欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=46be20911056)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785322, encodeId=c9a91e853228d, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, objectType=article, longId=188519, objectId=cccf188519dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cccf188519dd, replyNumber=0, likeNumber=78, createdTime=2020-04-04, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cccf188519dd, moduleTitle=PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cccf188519dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1785321, encodeId=17ce1e8532152, content=<a href='/topic/show?id=5a026e8428' target=_blank style='color:#2F92EE;'>#enfortumab#</a>, objectTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, objectType=article, longId=179625, objectId=df171e962513, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df171e962513, replyNumber=0, likeNumber=71, createdTime=2020-07-25, rootId=0, userName=12498cb5m13暂无昵称, userId=838d2500169, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df171e962513, moduleTitle=Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df171e962513)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

enfortumab

2020-05-29

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

Padcev（enfortumab vedotin）在欧盟获准治疗晚期尿路上皮癌

2022-07-01

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

NEJM：Enfortumab vedotin在晚期尿路上皮癌患者中的作用

2021-06-18

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

Lancet oncol：Enfortumab vedotin用于抗PD-1治疗后的铂不适用的局部晚期或转移性尿路上皮癌的疗效可期！

2021-07-09

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

ASCO GU 2021: ADC类药物Enfortumab Vedotin在尿路上皮癌中的治疗效果重磅公布（EV-301研究）

2021-10-14

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

EMA接受Astellas / Seagen的enfortumab vedotin的销售授权申请（MAA）

2021-12-23

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

欧洲药品管理局接受Enfortumab Vedotin的销售授权申请（MAA）

2021-09-30

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

PADCEV（enfortumab vedotin-ejfv）联合Pembrolizumab治疗晚期膀胱癌获得的FDA突破性疗法认定

2020-04-04

12498cb5m13暂无昵称 (审核中...)

前往app查看评论内容

#enfortumab#

Seattle Genetics和Astellas的抗体偶联药物enfortumab vedotin治疗局部晚期或转移性尿路上皮癌，喜获FDA的优先审查

2020-07-25

科室
- - 订阅+
  - 更多科室
工具
服务